FDA: Young-blood transfusions provide ‘no proven clinical benefit’ for aging, Alzheimer’s
A new FDA warning marks its sharpest rebuke to date of an industry claiming the blood of young donors can rejuvenate aging people.
The quest to rejuvenate aging people with the blood of young donors has generated paying customers, captured the popular imagination, and, now, prompted a warning from the Food and Drug Administration.
The agency on Tuesday that plasma infusions from young people provide “no proven clinical benefit” against normal aging, Alzheimer’s
